Campath in Chronic GVHD

Completed · Phase 1

Conditions studied: Chronic Graft-vs.-Host Disease

In brief

The CD52 antigen, which is targeted by alemtuzumab, is highly expressed on mature T lymphocytes, monocytes and monocyte-derived dendritic cells as well as on mature B cells. Due to its more promiscuous effect on immune cells, alemtuzumab not only targets antibody producing B lymphocytes as does rituximab, but also targets alloreactive T lymphocytes and dendritic cells that also contribute to the complex pathogenesis of chronic GVHD. Our hypothesis is that alemtuzumab will be effective in the treatment of chronic GVHD through its promiscuous depletion of alloreactive T lymphocytes, dendritic cells as well as antibody producing mature B-lymphocytes.

Key facts

Study ID

NCT00495755

Run by

Dana-Farber Cancer Institute

People needed

13

Starts

2007-07-01

Expected to finish

2012-10-01

Last updated by the study team

2013-08-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Recipients of allogeneic stem cell transplantation using myeloablative or non-myeloablative conditioning regimens.
• Patients must be at least 180 days (6 months) from the allogeneic stem cell transplantation procedure.
• Patients must have steroid refractory chronic GVHD, defined as having persistent signs and symptoms of chronic GVHD despite the use of prednisone at < 0.5 mg/kg/day or 1 mg/kg every other day for at least 4 weeks in the preceding 12 months (or equivalent dosing of alternate corticosteroids) without complete resolution of signs and symptoms. Patients with either extensive chronic GVHD or limited chronic GVHD requiring systemic therapy are eligible.
• Stable dose of corticosteroids for 4 weeks prior to enrollment.
• Less than 2mg/kg/day prednisone use (or equivalent).
• No addition or subtraction of other immunosuppressive medications (e.g. calcineurin inhibitors, sirolimus, mycophenolate mofetil) for 4 weeks prior to enrollment. The dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug.
• Adequate bone marrow function indicated by:
• ANC>1000/mm3
• Platelets>50,000/mm3
• Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment

You may not qualify if…

• Prednisone requirement>2mg/kg/day or equivalent
• Known life-threatening hypersensitivity to alemtuzumab, other anti-B cell or anti-T cell antibodies.
• Prior exposure to any new immunosuppressive medication (or Extra Corporeal Phototherapy) in the preceding 4 weeks prior to enrollment.
• Active, uncontrolled infection.
• History of Hepatitis B or C infection.
• Active malignant disease relapse.
• Donor lymphocyte infusion within the preceding 100 days or plan for donor lymphocyte infusion in the coming 3 months.
• Life expectancy <3 months.
• Pregnancy or lactation.
• Evidence of HIV seropositivity.
• Inability to comply with alemtuzumab treatment regimen.

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.